Genocea Biosciences, Inc. (NASDAQ:GNCA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday. The firm presently has a $1.75 target price on the biotechnology company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 9.37% from the company’s previous close.

According to Zacks, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other research analysts also recently issued reports on the stock. ValuEngine downgraded shares of Genocea Biosciences from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 26th. Needham & Company LLC downgraded shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Cowen and Company reiterated a “buy” rating and set a $10.00 target price on shares of Genocea Biosciences in a research report on Tuesday, September 26th. Stifel Nicolaus downgraded shares of Genocea Biosciences from a “buy” rating to a “hold” rating and dropped their target price for the company from $15.00 to $2.50 in a research report on Monday, September 25th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $18.00 target price (up previously from $17.00) on shares of Genocea Biosciences in a research report on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $9.48.

Genocea Biosciences (GNCA) traded down 0.62% during midday trading on Monday, reaching $1.60. 659,449 shares of the company’s stock traded hands. The firm’s market cap is $45.80 million. Genocea Biosciences has a 1-year low of $1.13 and a 1-year high of $7.29. The stock’s 50 day moving average price is $3.66 and its 200 day moving average price is $5.12.

Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.54) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.08). Equities research analysts anticipate that Genocea Biosciences will post ($1.92) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Genocea Biosciences, Inc. (GNCA) Stock Rating Upgraded by Zacks Investment Research” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/10/16/genocea-biosciences-inc-gnca-stock-rating-upgraded-by-zacks-investment-research.html.

In related news, CFO Jonathan Poole sold 45,000 shares of the business’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $6.00, for a total transaction of $270,000.00. Following the transaction, the chief financial officer now owns 84,247 shares in the company, valued at approximately $505,482. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.70% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the stock. FMR LLC raised its holdings in Genocea Biosciences by 0.4% during the first quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock worth $26,033,000 after buying an additional 18,574 shares during the last quarter. Northpointe Capital LLC raised its holdings in Genocea Biosciences by 9.6% during the second quarter. Northpointe Capital LLC now owns 1,336,062 shares of the biotechnology company’s stock worth $6,974,000 after buying an additional 117,374 shares during the last quarter. Vanguard Group Inc. raised its holdings in Genocea Biosciences by 13.9% during the second quarter. Vanguard Group Inc. now owns 856,762 shares of the biotechnology company’s stock worth $4,472,000 after buying an additional 104,790 shares during the last quarter. State Street Corp raised its holdings in Genocea Biosciences by 1,595.2% during the second quarter. State Street Corp now owns 366,172 shares of the biotechnology company’s stock worth $1,912,000 after buying an additional 344,572 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in Genocea Biosciences by 642.9% during the second quarter. Northern Trust Corp now owns 306,597 shares of the biotechnology company’s stock worth $1,601,000 after buying an additional 265,328 shares during the last quarter. Institutional investors own 59.25% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Analyst Recommendations for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.